Furthermore, knockdown of FOXM1 can also reduce VEGF-A levels in CRC cell lines, indicating that FOXM1 could be a selective target for the molecularly targeted treatments of CRC (174). The gene discussed is VEGFA; the disease is colorectal carcinoma.